Monographie - Fosphenytoin sodium

Última actualización :
19/11/2024

Fosphenytoin sodium

Factores que influyen sobre la estabilidad

Estructura química

Nombre comercial

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Cerebryx	Canadá, Estados Unidos de América
Fosphen	India
Fostoin	Japón
Pro - Epanutin	Austria, Dinamarca, Finlandia, Gran Bretaña, Irlanda, Islandia, Luxemburgo, Noruega, Países Bajos, Suecia
Prodilantin	Alemania, Austria, Bélgica, Dinamarca, Estados Unidos de América, Finlandia, Francia, Gran Bretaña, Grecia, Hungría, Irlanda, Islandia, Italia, Japón, Luxemburgo, Países Bajos, Polonia, Suecia, Suiza

Bibliografía : Fosphenytoin sodium

	Tipo	Publicación
800	periódico	Fischer JH, Cwik MJ, Luer MS, Sibley CB, Deyo KL. Stability of fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes. Ann Pharmacotherapy 1997 ; 31: 553-559.
1412	periódico	Brett A, Riggs RM, Webster AA, Benner KW. Y-site stability of fosphenytoin and sodium phenobarbital. Int J Pharm Compound 1999 ; 3: 64-66.
1419	periódico	Riggs RM, English BA, Webster AA, McGuire JM, Riordan JM. Fosphenytoin Y-site stability studies with lorazepam and midazolam hydrochloride. Int J Pharm Compound 1999 ; 3: 235-238.
1803	periódico	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
3379	periódico	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3827	póster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3829	póster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3967	periódico	Staven V, Herra I, Wang S, Grönlie I,Tho I. Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol 2017 ;69,7:448-462
4145	periódico	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4370	periódico	Staven V, Wang S, Gronlie I, Tho I. Physical stability of an all-in one parenteral nutrition admixture for preterm infants upon mixing with micronutrients and drugs EJHP 2018 2018;0:1-7
4428	periódico	Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4433	periódico	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4569	periódico	Lee T.M , Villareal C.L, Meyer L.M. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications. Hosp Pharm 2021 ; 56, 4: 282-286.
4801	periódico	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales